Phosphate sequence study of Boqueirâo pegmatite (Rio Grande Do Norte State, Brazil)

The Boqueirão pegmatite is located in the Borborema Pegmatite Province in the state of Rio Grande do Norte (NE Brazil) hosted by Neoproterozoic taconglomerates of Equador Formation. The pegma tite occurs as a concentric body displaying characteristic units according their mineralogy. The border and wall zones are composed by quartz, microcline and muscovite often displaying skeletal and graphic textures with accessory tourmaline and garnet. The intermediate zone is divided in two distinct subzones and shows a complex mineralogy exhibiting a varied phosphate association, beryl, columbite -tantalite and zircon. The innermost zone is mainly constituted by a quartz core. In addition, typical replacement bodies of albite are recognized at the eastern part of the body. Lithiophilite triphylite represents the most abundant phosphate phase exhibiting exsolutions of sarcopside and replaced by sicklerite due to Lileaching alteration, best known as Quensel Mason sequence .The scarcity of heterosite -purpurite series is remarkable. Montebrasite and triplite are also primary phosphates observed. Subsequently ,the presence of alluaudite and varulite occurrences suggests that Na-metasomatism affected the pegmatite. The whole ensemble is crosscut by an extensive alteration that resulted in secondary phosphate minerals . Electron microprobe data of triphylite-lithiophilite shows Mn/(Mn+Fe)ratios between 0.21-0.24 but also up to 0.72 which seems to indicates that the earlier pegmatite magma could be slightly fractionated; consequently,ferrisicklerite shows Mn/(Mn+Fe) values between 0.69 -0.77 in agreement with high evolution degree and suggesting that pseudomorphism may be produced by high rock/fluid ratios. Alluaudite and varulite also record Mn and Fe contents up to 0.71 similar to precursor phosphates. Furthermor eight different secondary phosphates have been identified as replacement of primary phases either as pseudomorphs or crosscutting them. They form euhedral crystals of fine grain size, spherulites or extensive masses displaying vivid colours which are ea sily identifiable. Manrich secondary phases are hureaulite, eosphorite, whiteite, jahnsite and serrabrancaite while lipscombite, phosphosiderite and mitridatite correspond to Ferich secondary association. Supergenic late origin and entrance of Ca-K,Mgrich fluids from host rock may be invoked in order to explain their formation. They do not show any relationship with processes of pegmatite crystallization. Hf content of zircon from the intermediate zone has been analysed by electron microprobe as a pow erful indicator of pegmatite evolution degree together with Mn content of phosphates. Hf content obtained is low up to 5% wt. of HfO which which points out to low fractionated pegmatite magma. Besides, the presence of ferromagnesian silicates forming the pegmat ite units such as Ferich tourmaline, garnet and green beryl is in agreement of that hypothesis. Therefore, Boqueirão corresponds to rare element pegmatite of beryl columbite phosphate subtype

IMPACTO DO ARTESANATO NA QUALIDADE DE VIDA DA COMUNIDADE DE PORTO DOS BARCOS, MUNICÍPIO DE ITAREMA, ESTADO DO CEARÁ

O objetivo deste artigo é analisar o impacto do artesanato na qualidade de vida da comunidade de Porto dos Barcos, do município de Itarema, Estado do Ceará. Para isso, foi construído um Índice de Qualidade de Vida, utilizando uma metodologia sugerida por Khan (2000), com o objetivo de verificar o nível de qualidade de vida nas comunidades estudadas. Os resultados mostraram que, após a implantação de um projeto de artesanato na comunidade de Porto dos Barcos, as famílias desta comunidade, passaram a ter uma melhor qualidade de vida. A comunidade controle (Barra do Farol), ainda possui uma qualidade de vida melhor que a de Porto dos Barcos, mas o crescimento da qualidade de vida de Porto dos Barcos foi consideravelmente melhor.-----------The objective of this paper is to analyze the impact of handicraft in quality of life of Porto dos Barcos community, in Itarema County, Ceará State, Brazil. Therefore, was built an Index of Quality of Live, using a methodology suggested by Khan (2000), with the objective of verifying the level of quality of life on the county studied. The results showed that, after the handicraft implantation of Porto dos Barcos community, the families of this community, started to have a better quality of life. The control community (Barra do Farol), still have a better quality of life than Porto dos Barcos, but the growth of quality of life of Porto dos Barcos was considerably.Artesanato, Qualidade de vida, Município de Itarema, Handicraft, Quality of Life, Itarema County, Community/Rural/Urban Development,

Simulação de diferentes arranjos de sistemas integrados em áreas de várzea / Simulation of different arrangements of integrated systems in lowland areas

Nos últimos anos, o aumento dos custos dos insumos para a produção, não acompanhado pelo aumento dos valores das comodities, fez com que as margens da agricultura brasileira menores. Neste contexto, os sistemas integrados de produção agropecuária ganham representatividade. Com isso, o objetivo deste trabalho foi simular, através da utilização de planilhas eletrônicas, diferentes arranjos de sistemas de integração lavoura pecuária, em áreas de várzea, para verificar a viabilidade econômica de cada sistema. Os cenários selecionados foram: i) arroz e soja alternadamente sem a utilização da área no inverno para a produção animal; ii) arroz e soja alternados e no período de inverno recria de terneiros em pastagem de azevém, sistema (ping-pong); eo terceiro sistema iii) simula uma rotação de talhão onde são cultivados dois anos de arroz e 3, 5 anos de pecuária em pastagens cultivadas. Como resultados do trabalho, foram observados altos custos para o cultivo das lavouras, principalmente para a cultura do arroz que atingiu R $5.980,57 / ha, sendo que a soja foi de R$ 2.764,77 / ha, o que resultou em uma baixa rentabilidade para esse sistema. No cenário que representa somente a rotação agrícola Arroz-Soja, a receita líquida anual foi de R $95,46 / ha / ano, já quando a pecuária foi inserida ao sistema, houve um incremento da lucratividade do cenário, onde nenhum sistema ping- pong a receita líquida anual foi de R$ 320,28 / ha / ano e para o sistema de rotação de talhão R $R$ 756,41 / ha / ano, média anual do sistema. Portanto, verificou-se que os sistemas de integração lavoura-pecuária aumentam a rentabilidade das propriedades, além de prover outros benefícios para as lavouras

Desfecho atípico de colesteatoma de orelha média: relato de caso

O presente estudo objetivou descrever um caso de colesteatoma de orelha média com recidiva após remoção cirúrgica, seguido por desfecho atípico. Paciente do sexo masculino, 40 anos, procurou atendimento médico com queixa de otalgia e plenitude auricular em ouvido esquerdo. Foi realizada ressonância magnética que evidenciou conteúdo líquido e células mastoideas ocupando a cavidade timpânica esquerda, com focos de restrição à difusão na caixa timpânica e antro medindo cerca de 1,4 cm, sendo compatível com colesteatoma de orelha média esquerda. O paciente foi, então, submetido a dois procedimentos cirúrgicos (uma timpanoplastia endoscópica e uma mastoidectomia fechada), num intervalo de quatro meses, para remoção total do tumor. Após 3 anos e 6 meses, o paciente apresentou recidiva para o colesteatoma. No dia anterior à cirurgia marcada para remoção do tumor recidivado, foi constatado, por ressonância magnética, a ausência do colesteatoma, o que sugere uma cura espontânea. A cura ou desaparecimento natural do tumor abre novas perspectivas de investigação para as ciências médicas

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study

Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe

The SIB Swiss Institute of Bioinformatics' resources: focus on curated databases

The SIB Swiss Institute of Bioinformatics (www.isb-sib.ch) provides world-class bioinformatics databases, software tools, services and training to the international life science community in academia and industry. These solutions allow life scientists to turn the exponentially growing amount of data into knowledge. Here, we provide an overview of SIB's resources and competence areas, with a strong focus on curated databases and SIB's most popular and widely used resources. In particular, SIB's Bioinformatics resource portal ExPASy features over 150 resources, including UniProtKB/Swiss-Prot, ENZYME, PROSITE, neXtProt, STRING, UniCarbKB, SugarBindDB, SwissRegulon, EPD, arrayMap, Bgee, SWISS-MODEL Repository, OMA, OrthoDB and other databases, which are briefly described in this article

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure &lt; 100 mmHg (n = 1127), estimated glomerular filtration rate &lt; 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation